retatrutide fda approval timeline 2025 Timeline: Week-by-Week Results (48 Weeks) FDA Warns Companies Over Compounded

[Gut-Driven Sugar Spike Support] Helps maintain healthy sugar levels already within normal range

Consideration GLP-1 (Semaglutide) GLP-1 + GIP (Tirzepatide) New to medical weight loss programs Want to target appetite regulation and digestion speed Need added support for insulin response & fat metabolism Have tried GLP-1 therapy before without desired results Prefer to start with one mechanism before adding a second Interested in dual-hormone approach for multiple pathways 2x weekly dosing and personalized guidance Which GLP weight loss program is right for you

That sequence is why a 2026 approval, which some less-careful coverage still suggests, does not match the underlying schedule

The bottom line GLP-1 drugs are not a replacement for insulin, and they are not officially approved for T1D (outside of the new 2026 ADA recommendation for T1D with obesity)

This aligns strongly with Ascend Medical's philosophy: medication plus lifestyle support equals meaningful, sustainable transformation

Dosage conversion: switching between compounds There is no established dose conversion between retatrutide and tirzepatide